Source: Financial Times [UK]
“Goldman Sachs Asset Management has agreed a more than €2bn deal to acquire drugmaker Synthon from BC Partners, according to people familiar with the matter, as it hopes to capitalise on demand for off-patent versions of complex medicines. Private equity group BC Partners, which acquired a majority stake in the business in 2019 at an enterprise value of €750mn, will retain a roughly 25 per cent stake in the group after the Goldman Sachs deal, one of the people said. … Synthon specialises in developing and manufacturing generic versions of complex drugs. Its portfolio includes treatments for cancer, cardiovascular conditions and multiple sclerosis.” (12/16/24)